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Abstract
We study a five-compartment mathematical model originally proposed by Kuznetsov et al. (1994) to investigate the effect
of nonlinear interactions between tumour and immune cells in the tumour microenvironment, whereby immune cells may
induce tumour cell death, and tumour cells may inactivate immune cells. Exploiting a separation of timescales in the
model, we use the method of matched asymptotics to derive a new two-dimensional, long-timescale, approximation of
the full model, which differs from the quasi-steady-state approximation introduced by Kuznetsov et al. (1994), but is
validated against numerical solutions of the full model. Through a phase-plane analysis, we show that our reduced model
is excitable, a feature not traditionally associated with tumour-immune dynamics. Through a systematic parameter
sensitivity analysis, we demonstrate that excitability generates complex bifurcating dynamics in the model. These are
consistent with a variety of clinically observed phenomena, and suggest that excitability may underpin tumour-immune
interactions. The model exhibits the three stages of immunoediting – elimination, equilibrium, and escape, via stable
steady states with different tumour cell concentrations. Such heterogeneity in tumour cell numbers can stem from
variability in initial conditions and/or model parameters that control the properties of the immune system and its response
to the tumour. We identify different biophysical parameter targets that could be manipulated with immunotherapy in
order to control tumour size, and we find that preferred strategies may differ between patients depending on the strength
of their immune systems, as determined by patient-specific values of associated model parameters.
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1. Introduction
Cancer ranks as one of the leading causes of death
worldwide, with millions of new cancer cases diagnosed
every year, and incidence and mortality rates rapidly grow-
ing (Bray et al., 2018). Despite being toxic and lacking
specificity for tumour cells, chemotherapy and surgery, to-
gether with radiotherapy, remain the standard of care for
cancer patients. The ability of cancer to form metastases
makes it challenging to control by these treatments alone,
thereby raising the demand for complementary approaches
to cancer therapy.
In recent years immunotherapy has become an increas-
ingly important area of research. Understanding how treat-
ments, which harness the immune system to treat cancer,
may work provides the motivation for this study. The
central idea underpinning cancer immunotherapy is cancer
‘immunosurveillance’, whereby tumour detection is enabled
by tumour antigens. These antigens coat the tumour cell
surface and, due to genetic alterations, are sufficiently dif-
ferent from other self-antigens so as to be immunogenic.
∗Corresponding Author:
Email address: osojnik@maths.ox.ac.uk (Ana Osojnik)
The ability to detect tumour antigens allows the immune
system to target cancer cells for destruction.
Initiation, execution and regulation of a specific adap-
tive immune response is performed by a group of immune
cells called T cells. All T cells express T cell receptors
(TCRs) that are specific for a particular antigen. When
TCRs on a T cell match with cognate tumour antigens
presented on the surface of phagocytotic dendritic cells that
collect and process antigen material, the T cell is activated,
and becomes an effector T cell. Different subtypes of effec-
tor T cells perform complementary functions to eliminate
foreign cells. They proliferate, and secrete growth factors
and cytokines, through which also other immune cells en-
gage with the immune response to the tumour. Effector
cytotoxic T cells (CTLs) can travel to the tumour, where
they scan tumour cells until they find target cells, whose
presented antigens match their TCRs. Upon recognition,
CTLs programme target cells to die by apoptosis, either
by delivering a mixture of perforin and granzyme to target
cells or via engagement of the cell death surface receptor
Fas (Russell and Ley, 2002; Murphy and Weaver, 2016).
The above description summarises the key processes
involved in successful immunosurveillance. In practice,
however, multiple mechanisms enable tumour cells to es-
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cape immune elimination. The surviving, immunologi-
cally resistant tumour cells are maintained in a state of
immune-mediated equilibrium, with some cells undergo-
ing further division and editing. During this process, the
selective pressure exerted by the immune system can re-
sult in the emergence of new tumour cell variants that
can resist, avoid, or suppress immune attack (Swann and
Smyth, 2007). They may develop into clinically detectable
tumours, and establish an immunosuppressive environment,
enabling tumour progression. Dunn et al. (2004) termed
this process immunoediting, proposing three possible out-
comes of tumour-immune interactions, called ‘the three Es
of immunoediting’: tumour elimination, equilibrium, and
escape.
In order to re-establish self-sustaining immunity to can-
cer, the objective of some immunotherapies is to target
specific mechanisms of tumour escape from immunosurveil-
lance. A variety of strategies have been proposed and the
most effective ones are now being combined with stan-
dard treatments in the clinic (Emens et al., 2017). These
immunotherapies include: immune checkpoint inhibitors,
which block immunosuppressive pathways, activated in a
healthy organism to prevent over-inflammatory responses
and minimize tissue damage (Pardoll, 2012); therapeu-
tic dendritic cell vaccine, which boosts the population of
dendritic cells that present tumour-associated antigens to
effector T cells (Hammerstrom et al., 2011); and adoptive
T cell transfer therapy, which induces tumour specificity in
the population of effector T cells via genetic engineering or
antigen-specific expansion (Baruch et al., 2017). Despite
many successes, even the most promising immune check-
point inhibitors have seen average response rates of less
than 50% (Lipson et al., 2015; Grywalska et al., 2018). To
increase the fraction of responsive patients, better under-
standing of the complex interactions between the tumour
and the immune system is needed.
With increasing recognition of mathematical modelling
as a tool to gain mechanistic insight, a variety of models
have been devised to explain clinically observed features
of tumour-immune interactions. These models vary from
spatial to non-spatial models, deterministic to stochastic,
continuous to discrete, single scale to multiscale. The most
commonly used framework, also employed in this paper,
involves the use of ordinary differential equations (ODEs)
that capture spatially-averaged, time-varying dynamics
at the population level. Other models are formulated in
terms of stochastic differential equations (Lefever and Hors-
themke, 1979; Bose and Trimper, 2009; Xu et al., 2013;
Liu et al., 2018), partial differential equations (Matzavinos
et al., 2004; Webb et al., 2007; Lai et al., 2017; Fried-
man and Lai, 2018), integro-differential equations (Bel-
lomo et al., 2007), agent-based models (Owen et al., 2011;
Baar et al., 2016; Macfarlane et al., 2018) or hybrid mod-
els (Mallet and de Pillis, 2006; Lo´pez et al., 2014; Gong
et al., 2017). The simplicity of ODEs renders them more
analytically tractable and easier to validate than other
approaches, while still capturing the essential features of
tumour-immune interactions. Some ODE models describe
tumour-immune interactions by analogy with predator-prey
models, with effector T cells as predators and tumour cells
as prey (Kuznetsov et al., 1994; Sotolongo-Costa et al.,
2003; de Vladar and Gonza´lez, 2004; D’Onofrio, 2005; Fras-
coli et al., 2014; Dritschel et al., 2018). For an exhaustive
review of ODE models of tumour-immune interactions we
refer the reader to Eftimie et al. (2011) and Wilkie (2013).
In this paper we study the model by Kuznetsov et al.
(1994), which was proposed to explain the phenomena of
tumour dormancy/equilibrium, sneaking through (when
small tumours fail to induce immune responses and grow
to escape, while medium tumours are contained by the
immune system; Gatenby et al., 1981), and immunostim-
ulation (when stimulation of immune response leads to
progressive tumour growth rather than elimination). The
five-compartment model describes interactions between
effector and tumour cells through the formation of an inter-
mediate effector-tumour complex. The model incorporates
immune killing of tumour cells, tumour-induced suppres-
sion and anergy of effector cells, and limits on immune
recruitment and proliferation when the tumour grows large.
Kuznetsov et al. (1994) perform model reduction by assum-
ing that the timescale on which tumour and effector cells
form complexes is much shorter than the timescale of other
processes, such as effector cell proliferation and recruitment
to the tumour site. A quasi-steady-state approximation
(QSSA) is made, under which the model reduces to two
ODEs that describe the dynamics of the effector and tu-
mour cells; the complexes vary parametrically with these
variables. Kuznetsov et al.’s analysis of the QSSA model’s
bifurcations reveals how variation in the influx rate and
death rate of effector cells affects system dynamics; the
model exhibits tumour escape, equilibrium or elimination,
or coexistence (bistability) of small-tumour or tumour-free
steady states with escape. Occurrence of sneaking through
and immunostimulatory effects in this model is found to
depend on the rate of effector cell inactivation inflicted by
tumour cells.
The QSSA model of Kuznetsov et al. (1994) has been
used and modified in numerous studies. By relaxing as-
sumptions about effector cell recruitment and proliferation,
Ga lach (2003) proposed a simpler model that captures the
three Es of immunoediting in different parameter regimes.
Roesch et al. (2014) adapted the QSSA model to study
the impact of chemotherapy on large B cell lymphoma.
Dritschel et al. (2018) introduced a helper T cell compart-
ment to the QSSA model by Kuznetsov et al. (1994) to
distinguish immune cell promotion and tumour cell killing,
and implicitly incorporated tumour-modulated immuno-
supression by altering the functions describing immune
recruitment and proliferation. In addition to the three Es
of immunoediting, their model exhibits periodic growth
and suppression of the immune and tumour populations,
unlike the QSSA model by Kuznetsov et al. (1994). Oscil-
latory dynamics have been observed in extensions of the
QSSA model that include time delays to account for the
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delay between antigen recognition and immune response
(Ga lach, 2003; Rihan et al., 2014). Other authors adapted
the QSSA model by incorporating interactions with healthy
cells (de Pillis and Radunskaya, 2001) or natural killer (NK)
cells (de Pillis et al., 2005). While Kuznetsov et al.’s QSSA
model and its modifications have been studied extensively,
the validity of the QSSA model or the dynamics of their
original model have not been.
Parameters in such ODE models may vary for a variety
of reasons. Parameters estimated from clinical data will
have uncertainties associated with them, and parameters
may vary between patients, depending on factors such as
the aggressiveness and immunogenicity of their tumours, or
the strength of their immune responses. Administration of
chemo- and/or immunotherapy may also alter one or more
model parameters. The effects of parameter perturbations
on model behaviour are therefore analysed to uncover the
full range of model dynamics. For example, Kirschner and
Panetta (1998) investigated the impact of administering
the cytokine interleukin-2 (IL-2) and adoptive cell therapy
(ACT), separately and in combination. In their model,
which is similar to the QSSA model with addition of an IL-2
compartment, parameters controlling the (constant) supply
rates of IL-2 and immune cells were varied to model the
effects of IL-2 and ACT. In this way ACT as a monotherapy
or combined with IL-2 was found to be more beneficial for
the patient than IL-2 alone as a monotherapy. Dritschel
et al. (2018) thoroughly explored the parameter space of
their model incorporating helper T cells to demonstrate
that targetting the helper T cell population with ACT
may be more effective than targetting the cytotoxic T cell
population.
In this paper we study Kuznetsov et al.’s original model
of tumour-immune interactions. We explore the validity of
the QSSA, and investigate the complex tumour-immune
dynamics that emerge from the original model. Using
asymptotic, phase-plane and bifurcation analysis, in com-
bination with numerical techniques, we identify parameter
regimes in which the model admits similar dynamics to
the QSSA model described above, and other regimes in
which it admits limit cycles and excitability; the latter
has to our knowledge not been traditionally identified as a
feature of existing models of tumour-immune interactions.
We place the resulting mechanistic insights within the con-
text of immuno-oncology, and the theoretical prospect of
implementing tumour control.
The remainder of this article is organised as follows.
In Section 2 we describe the original model of Kuznetsov
et al. (1994). In Section 3 we exploit the separation of
timescales, which arises due to fast conjugate dynamics,
to perform an asymptotic reduction of the original model.
The reduced model we obtain differs from the QSSA model
derived in Kuznetsov et al. (1994), but agrees with numeri-
cal simulations of the original model where the asymptotic
approximation is valid. In Section 4 we use phase-plane
methods to show that our reduced model is excitable, while
in Section 5 we characterise the model’s bifurcation struc-
ture as the supply and death rates of effector cells vary,
and show how sensitive this is to variability in parameters
associated with the immune reponse to the tumour. We
discuss our findings in Section 6, and explain how they can
be used to understand tumour-immune interactions and to
identify immunotherapeutic targets, represented by model
parameters, that may successfully eliminate a tumour.
2. Mathematical model
In this section, we summarise the original model pro-
posed by Kuznetsov et al. (1994), describe the assumptions
made about parameter values, and derive a dimensionless
version of the model. This will facilitate its simplification
and analysis of its long-term behaviour in later sections of
the paper. We end by stating the parameter values that
will be used for model analysis.
2.1. Kuznetsov et al.’s original five-compartment model
Kuznetsov et al. (1994) proposed a system of five,
time-dependent, nonlinear ordinary differential equations
(ODEs) to describe temporal interactions between effec-
tor and tumour cells in a well-mixed (spatially-uniform)
region, which represents the interface of the tumour and
its microenvironment, see Figure 1. Here the generic term
effector (immune) cells is used to refer to all cell types
capable of destroying tumour cells when activated, noting
that these cells are anticipated to be predominantly CTLs.
In their model, both tumour and effector cells may exist in
a functional state, in which they may interact with other
cells, or in a dysfunctional state, in which they are unable
to interact with other cells. Accordingly, the tumour cell
population is split into normal tumour cells, M(t), and
lethally hit (marked for death) tumour cells, M∗(t), while
the effector cell population is divided into activated effector
cells, E(t) and inactivated effector cells, E∗(t). The model
also includes an intermediate state, C(t), associated with
the formation of conjugates, when an activated effector cell
and a normal tumour cell come in contact.
The evolution of the normal tumour cell population
is governed by their proliferation, and programmed cell
death due to interactions with effector cells. Prolifera-
tion is modelled via a logistic growth term aM(1 − bM),
where the positive constant a (units: day−1) is the basal
growth rate, and the reciprocal of the positive parameter
b (units: cells−1) is the carrying capacity of the tumour
site. Tumour cell programmed death, induced by effector
cells, is modelled as a transition from the functional state,
M , to the dysfunctional state, M∗, that is assumed to
occur via effector-tumour conjugates, C; the inactivation
of effector cells occurs in a similar manner. Conjugates are
assumed to form at rate k1EM , which is proportional to
the functional effector and tumour cell numbers, with con-
stant of proportionality k1 (units: cell−1day−1). There are
three possible outcomes for the resulting conjugate, which
may dissociate into (see solid arrows in Figure 1): (i) a
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Figure 1: Schematic showing how effector (green) and tumour (or-
ange) cells interact in the model of Kuznetsov et al. (1994). Kinetic
interactions are denoted with solid arrows, while birth, death and
migration processes are denoted with dashed ones. Arrows with
a straight line in place of an arrow head represent inhibition of a
process.
tumour cell, M , and an activated effector cell, E, at rate
k−1C, proportional to conjugate numbers, with constant
of proportionality k−1 (units: day−1); (ii) a lethally hit
(marked for programmed death) tumour cell, M∗, and an
activated effector cell, E, at rate k2C, which is proportional
to conjugate numbers, with constant of proportionality k2
(units: day−1); (iii) an inactivated (suppressed) effector
cell, E∗, and a tumour cell, M , at rate k3C, proportional
to conjugate numbers, with constant of proportionality k3
(units: day−1). Dysfunctional cells are assumed to arise
only by transitioning, via conjugates, from their respec-
tive functional compartments, and their ultimate fate is
death or migration out of the region. Programmed death
of lethally hit tumour cells, M∗, is assumed to occur at
rate d3 (units: day−1).
The evolution of the activated effector cells is assumed
to be dominated by their migration from the lymph nodes
to the tumour site, natural cell death, and inactivation by
tumour cells; the latter is assumed to occur as described
above. Migration to the tumour is modelled via a supply
term with two parts: a positive constant rate, s (units:
cells day−1), that represents a continuous baseline supply
of activated effector cells to the tumour, and a tumour-
stimulated rate, fCg+M , that accounts for an increase in the
rate of effector recruitment, proliferation, and infiltration
due to their interactions with tumour cells within conju-
gates; f (units: cells day−1) and g (units: cells) are positive
constants, such that f/g is the maximum effector supply
rate per complex, while g is the tumour cell concentration,
at which the influx rate per complex is half-maximal. The
factor (g +M)−1 ensures that the tumour-stimulated rate
of influx saturates as the number of tumour cells increases,
and accounts for limitations in the rate of stimulation of
the immune system, or in the rate of transport to and
through the tumour. Activated effector cells are assumed
to die at rate d1 (units: day−1). Similarly as for M∗(t),
the dysfunctional effector cells are assumed to die/migrate
out at rate d2 (units: day−1).
By combining the processes outlined above, we recover
the following ODEs for the different cell species that were
proposed by Kuznetsov et al. (1994):
dM
dt = aM(1− bMtot)︸ ︷︷ ︸
net proliferation
− k1EM︸ ︷︷ ︸
conjugate
formation
+ (k−1 + k3)C︸ ︷︷ ︸
conjugate
dissociation
w/o damage to
tumour cell
, (1a)
dE
dt = s︸︷︷︸
constant
supply
+ fC
g +M︸ ︷︷ ︸
tumour-
stimulated
supply
− d1E︸︷︷︸
death
− k1EM︸ ︷︷ ︸
conjugate
formation
+ (k−1 + k2)C︸ ︷︷ ︸
conjugate
dissociation
w/o damage to
effector cell
,
(1b)
dC
dt = k1EM︸ ︷︷ ︸
conjugate
formation
− (k−1 + k2 + k3)C︸ ︷︷ ︸
conjugate dissociation
, (1c)
dM∗
dt = k2C︸︷︷︸
tumour cell
marking
for death
− d3M∗︸ ︷︷ ︸
programmed
death
, (1d)
dE∗
dt = k3C︸︷︷︸
effector cell
inactivation
− d2E∗︸ ︷︷ ︸
death or
migration
. (1e)
We close equations (1a)–(1e) by prescribing the following
initial conditions:
E(0) = E0, M(0) = M0, C(0) = 0, (1f)
E∗(0) = 0, and M∗(0) = 0, (1g)
where the positive constants E0 and M0 denote the ini-
tial concentrations of free tumour cells and effector cells
respectively. Noting the impact on the subsequent model
solutions is essentially negligible, no conjugates, C, and
dysfunctional cells, M∗ and E∗, are present initially. We
note from equations (1) that the dynamics of M∗ and E∗
are slave to those of M , E and C. Since the system be-
haviour can be determined from equations (1a)–(1c), we
henceforth focus on these.
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2.2. Parameter assumptions and the dimensionless model
We nondimensionalise equations (1a)–(1c) and (1g) by
rescaling model variables as follows:
e = E/Eˆ, m = M/Mˆ, c = C/Cˆ, τ = k2t, (2a)
where Eˆ and Mˆ are positive constants (see Table 1). The
scaling for C is chosen as Cˆ = k1EˆMˆK with K = k−1+k2+k3,
in order to balance terms in equation (1c) for C. We define
the dimensionless parameter groupings as
σ = s
k2Eˆ
, ρ = fk1
k2K
, η = g
Mˆ
, δ = d1
k2
, (2b)
µ = k3k1Mˆ
k2K
, κ1 =
k1Mˆ
K
, α = a
k2
, β = bMˆ, (2c)
κ2 =
k1Eˆ
K
= κ1
Eˆ
Mˆ
. (2d)
Additionally, we identify a small dimensionless parameter
grouping
0 < ε = k2
k−1 + k2 + k3
= k2
K
 1. (2e)
The choice of ε is based on the observation that while
effector cells constantly scan and interact with tumour cells
in order to locate their target cell, only a small proportion
of these interactions result in the marking of tumour cells
for death, or inactivation of effector cells. For this to hap-
pen, the tumour antigen must be cognate to the TCR, but
this is not the case at every effector-tumour interaction due
to heterogeneity in repertoires of tumour antigens (Chen
and Mellman, 2013; Rajasagi et al., 2014; Boyer et al.,
1989) and TCRs at the tumour site (Dovedi et al., 2017).
The average kinetics of tumour cell programmed death and
effector cell inactivation is therefore slow in comparison to
conjugate formation and dissociation without damage. In
terms of parameter values, we thus assume that the per
cell rates k−1 and k1Eˆ, are large in comparison to k2 and
k3, i.e. k1Eˆ = O(k−1), k2  k−1, and k3 = O(k2) k−1.
Given our interest in the long-term behaviour, we scale the
model with one of the longer timescales, choosing k−12 as
in Kuznetsov et al. (1994). Following their reasoning for
applying the QSSA, we further assume that kinetics of pro-
cesses such as cell death, proliferation and migration to the
tumour microenvironement are also much slower than kinet-
ics of conjugate formation and dissociation without damage,
and we assume they are approximately comparable to those
of tumour cell programmed death and effector cell inactiva-
tion; we therefore have s
Eˆ
, fk1K , d1, a = O(k2)  k−1. In
summary, there is a separation of timescales, with a number
of events associated with the complexes occurring rapidly.
We will see in Section 2.3 that our parameter assumptions
correspond with parameter values from Kuznetsov et al.
(1994), given in Table 1. We note that these assumptions
represent a distinguished limit, and estimates of parameters
k1 and k−1 are needed to provide additional support for it.
Under the assumptions outlined above, equations (1)
can be rewritten in dimesionless form using rescalings in
(2):
de
dτ = σ +
ρc
η +m − δe− µc−
κ1
ε
(em− c), (3a)
dm
dτ = αm(1− βm)− κ2c−
κ2
ε
(em− c), (3b)
dc
dτ =
1
ε
(em− c), (3c)
with initial conditions
e(0) = E0/Eˆ =: e0, m(0) = M0/Mˆ =: m0,
and c(0) = 0.
(3d)
In the remainder of this work, we use dimensionless forms
of variables and parameters.
2.3. Parameter values
We use the dimensional parameter values given in Ta-
ble 1, which were estimated in Kuznetsov et al. (1994)
from tumour growth curves for B cell lymphoma in the
spleen of mice (Siu et al., 1986), and using information
about effector cell kinetics in tumour absence. The corre-
sponding dimensionless parameter values are computed in
Parameter Description Value
a net tumour growth rate 0.18 day−1
b inverse carrying capacity 2.0× 10−9 cell−1
d1 per cell death rate of activated effector cells 0.0412 day−1
f ‘maximum” tumour-stimulated effector supply rate per complex 1.245× 105 cells day−1
g Michaelis-Menten-type constant 2.019× 107 cells
k2 rate of effector inactivation 0.1101 day−1
k3 rate of tumour kill 3.422× 10−4 day−1
s constant effector supply rate to the tumour site 1.3× 104 cells day−1
Eˆ, Mˆ, Cˆ, K
k1
typical tumour cell numbers 106 cells
Table 1: Summary of the dimensional parameters that appear in the dimensional model (1), as estimated in Kuznetsov et al. (1994). The
logistic growth parameters, a and b, were estimated from tumour growth data for a non-chimeric mouse, where tumour mass was assumed to
grow in the absence of immune response. Under premises that the system is in steady state in tumour absence, with the steady state number
of effector cells in the region being E∗ = 3.2× 105, and that the lifetime of cytotoxic T cells is 30 days or more, i.e. d1 ≈ 1/30 days−1, the
constant influx rate s is estimated to be s ≈ E∗d1. Other parameters are estimated using data for a chimeric mouse with an immune system.
Values for scalings of variables, Eˆ and Mˆ , are chosen from experiments to be order-of-magnitude numbers of tumour cells, this is 106 cells.
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Parameter Description Value
α net tumour growth rate 1.6348
β inverse carrying capacity 0.002
δ per cell death rate of activated effector cells 0.374
ρ “maximum” tumour-stimulated effector supply rate per complex 1.131
η Michaelis-Menten-type constant 20.19
µ rate of effector inactivation 0.003
σ constant effector supply rate to the tumour site 0.118
κ1, κ2 ratios of variable scales 1
Table 2: Summary of the dimensionless parameters that appear in the nondimensional model (3). Estimates of their values are computed from
dimensional parameters in Table 1 according to parameter groupings (2).
Table 2, by assuming that the ratio K/k1 = 106 cells, or
equivalently K/k1Eˆ ≈ 1. This agrees with our assumptions
about parameters stated in Section 2.2, and also implies
that κ1 = κ2 = 1.
3. Matched asymptotic model approximation
The dependence of equations (3) on the small parameter
0 < ε  1 means that the system operates on at least
two timescales. Exploiting this, we apply the method of
matched asymptotic expansions to equations (3) in order to
derive approximate equations that are simpler to analyse.
We first rewrite the model as a slow-fast system of
ordinary differential equations, with a clear difference in
the timescales governing the dependent model variables.
In other words, we seek to eliminate terms in (3a) and (3b)
that scale with 1/ε. We define
v(τ) := c(τ), (4a)
and w(τ) :=
[
w1(τ)
w2(τ)
]
=
[
e(τ) + κ1c(τ)
m(τ) + κ2c(τ)
]
, (4b)
where w1 and w2 are, in descriptive terms, the total num-
ber of effector and tumour cells respectively, and v is the
number of conjugates at the tumour site. With significant
algebra, differential equations that describe the evolution of
u(τ) := [v(τ),w(τ)T ]T take the desired form of a slow-fast
system of ODEs given by
ε
dv
dτ = f(v,w), (5a)
dw
dτ = g(v,w), (5b)
with initial conditions
v(0) = 0, w(0) = [w1,0, w2,0]T = [e0,m0]T , (5c)
and
f(v,w) := em− c = (w1 − κ1v)(w2 − κ2v)− v, (5d)
g(v,w) :=
[
σ + ρvη+w2−κ2v − δ(w1 − κ1v)− µv
α(w2 − κ2v)(1− β(w2 − κ2v))− κ2v
]
. (5e)
The singular nature of system (5), where some deriva-
tives are multiplied by the small parameter ε, means that
we cannot construct a uniformly valid solution by taking
the limit ε→ 0. We must consider separately approxima-
tions on the short and the long timescales, and match them
to obtain a uniformly valid approximation of the full model
solution u(τ). We denote the inner and outer solutions
by uI(τf ) and uO(τ) respectively, where τf denotes the
rescaled time variable on the short timescale, proportional
to the slow time variable τ via τf := τ/ε. The composite
matched solution uC(τ) (Hinch, 1991) is then given by
uC(τ) = uI(τ/ε) + uO(τ)− uoverlap, (6a)
where, to satisfy the initial conditions (3d), we impose
Prandtl’s matching condition
lim
τf→∞
uI(τf ) = lim
τ→0
uO(τ) = uoverlap. (6b)
We determine the inner and outer solutions in Sections 3.1
and 3.2.
3.1. Asymptotic approximation of fast dynamics
To analyse behaviour on the short timescale, we rescale
time in equations (5) via τf = τ/ε, and obtain the system
dv
dτf
= f(v,w), (7a)
dw
dτf
= εg(v,w). (7b)
Let us suppose that
vI(τf ; ε) =
∞∑
i=0
εiv
(i)
I (τf ), and wI(τf ; ε) =
∞∑
i=0
εiw
(i)
I (τf ),
(8)
are asymptotic expansions in ε, where subscript I denotes
the inner (short-timescale) model solution. By substituting
from (8) in (7) and equating terms of O(εi), we obtain a
sequence of differential equations. At leading order in ε we
obtain
dvI
dτf
= f (vI,wI) , (9a)
dwI
dτf
= 0, (9b)
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with initial conditions
vI(0) = 0, wI(0) = w0 = [w1,0, w2,0]T , (9c)
where uI(τf ; ε) ∼ u(0)I (τf ). For simplicity henceforth uI
will always represent the leading order approximation u(0)I .
Equations (9) imply that
wI(τf ) := wI(0) = w0 = [e0,m0]T = constant (10)
while dynamics of conjugates, vI, are governed by
dvI
dτf
= Av2I −BvI + C, (11a)
with
A = κ1κ2, B = 1 + κ2w1,I + κ1w2,I, C = w1,Iw2,I,
(11b)
where w1,I and w2,I are constants corresponding to initial
conditions (9c). For positive initial conditions w0 > 0 and
v0 = 0, we deduce that vI tends to a positive steady state
v∗I = v†(w0) satisfying f(v∗I ,w0) = 0 as τf → ∞, where
we define
v†(w) = 12κ1κ2
(1 + κ1w2 + κ2w1
−
√
(1 + κ1w2 + κ2w1)2 − 4κ1κ2w1w2
)
.
(12)
We conclude that, on the short timescale at leading order
in ε, the number of conjugates, vI, rapidly relaxes from
0 to v∗I = v†(w0), while the total numbers of tumour
and effector cells undergo negligible changes and are so
conserved at w∗I = w0. The numbers of free effector
and tumour cells, e and m, are depleted due to conjugate
binding to their steady state values e∗I = e†(w0) and m∗I =
m†(w0) respectively, where
e†(w) = w1 − κ1v†(w) = 12κ2 (κ2w1 − 1− κ1w2
+
√
4κ2w1 + (κ2w1 − 1− κ1w2)2
)
,
(13a)
m†(w) = w2 − κ2v†(w) = 12κ1 (κ1w2 − 1− κ2w1
+
√
4κ1w2 + (κ1w2 − 1− κ2w1)2
)
.
(13b)
Note that when the steady state [e∗I ,m∗I , c∗I ]T is reached,
dcI
dτf =
dvI
dτf = f(v
∗
I ,w
∗
I ) = 0, or v∗I = c∗I = e∗Im∗I , and
expressions (12) and (13) satisfy v†(w) = e†(w)m†(w).
3.2. Asymptotic approximation of slow dynamics
We now focus on the long timescale, for which the
dynamics of v are slave to the dynamics of w, i.e. v changes
parametrically with respect to w. On this timescale the
total effector and tumour cell numbers, w1 and w2, vary
significantly, since O(ε) terms in (7) become non-negligible.
Formally, we consider the long-timescale system (5), and
seek solutions for vO and wO of the form
vO(τ ; ε) =
∞∑
i=0
εiv
(i)
O (τ), and wO(τ ; ε) =
∞∑
i=0
εiw
(i)
O (τ).
(14)
At leading order in ε, we obtain the following equations
that approximate dynamics on the slow manifold,
dwO
dτ = g(vO,wO), (15a)
f(vO,wO) = 0. (15b)
According to (15b), vO must be a positive solution to
the quadratic (5d), which is the case exactly when vO =
v†(wO) as defined in (12), except that now wO is a time-
dependent variable on the long timescale. Initial condi-
tions for the outer (slow manifold) solution are given by
limτ→0 = [v†(w0),wT0 ]T , equivalent to the inner solution
steady state u∗I = [v∗I ,w∗I
T ]T given in Section 3.1, by which
the matching condition (6b) is automatically satisfied. On
the long timescale, the model reduces to
dw
dτ = g(v
†(w),w), (16)
or equivalently
dw1
dτ = σ +
ρe†(w)m†(w)
η +m†(w) − δe
†(w)− µe†(w)m†(w),
(17a)
dw2
dτ = αm
†(w)(1− βm†(w))− κ2e†(w)m†(w), (17b)
where we drop the subscript O notation for simplicity.
Equations (17) are highly nonlinear, deeming their analysis
difficult. To simplify the steady state and linear stability
analysis in later sections, we rewrite these (slow manifold)
equations in terms of the dimensionless variables e and m,
and obtain the following system of ODEs:[
e˙
m˙
]
=
[
1 + κ1m κ1e
κ2m 1 + κ2e
]−1 [
σ + ρemη+m − δe− µem
αm(1− βm)− κ2em
]
︸ ︷︷ ︸
=:q(e,m)
.
(18)
This contrasts with the Kuznetsov et al.’s QSSA model
given by equations (3) with c = em.
3.3. Comparison of numerical solutions
To confirm the accuracy of the asymptotic reduction,
we compare the solution of the full system (3) with the com-
posite solution (6). We solve the full system by integrating
equations (3) using the Python function scipy.integra-
te.odeint, a wrapper for the lsoda solver from Fortran’s
library odepack. This ODE solver automatically switches
between stiff and nonstiff methods, noting the system is
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Figure 2: Series of plots showing good agreement between the composite and full solutions of equations (5) on (a) the short timescale
(0 ≤ τ ≤ ε/10), where the inner solution dominates, and on (b) the long timescale (ε/10 ≤ τ ≤ 60), where the outer solution dominates. The
left, middle and right panel plots respectively show the solutions for model variables w1(τ), w2(τ) and v(τ) over time. The solutions are
computed numerically as described in Section 3.3, for initial conditions w1(0) = 301, w2(0) = 600, v(0) = 0, and default parameter values with
ε = 10−2.
stiff when the dynamics are fast. To construct the compos-
ite solution, we use the same solver to generate numerical
solutions for the fast and slow systems, whereby integration
of the governing equations for both systems is performed
with respect to the slow timescale τ . We then combine
numerical solutions using the matching condition (6).
The results presented in Figure 2 show that the full and
composite solutions are in good agreement for small and
large times, i.e. during the fast and slow dynamics. As
anticipated, O(ε) discrepancies in the composite solution
are observed on the short timescale. We conclude that the
matched asymptotic approximation of the full solution is
accurate within the expected error range, and note that the
solutions exhibit a rapid relaxation onto the slow manifold
dynamics. Based on these findings, we assert that the
reduced model associated with the long timescale charac-
terises the long-term dynamics of the full model, by which
we motivate its analysis in Sections 4 and 5.
Details on how the full and asymptotic long-timescale
solutions, i.e. solutions of equations (3) and (17) respec-
tively, compare with solutions of the QSSA model from
Kuznetsov et al. (1994) are provided in Appendix C.
4. Phase-plane analysis of slow dynamics
We now characterise the long-term behaviour of the
composite solution (derived in Section 3), by analysing
the reduced outer model defined by (17) using approaches
similar to those for the study of the Fitzhugh-Nagumo
(FN) equations, which model excitability in neuronal dy-
namics (Fitzhugh, 1961). A system is excitable if a small
perturbation from a stable steady state results in a large
excursion before the system relaxes back to the same or a
different steady state. Alternatively, the system may relax
onto a limit cycle with large excursions. In this section,
we show that our reduced system (17) exhibits excitable
tumour-immune dynamics.
4.1. Nullclines and excitability
On the w1- and w2-nullclines of the slow system (17)
we have w˙1 = 0 and w˙2 = 0 respectively. We find that
w1-nullclines are a subset of solutions to a quadratic in
w2, which has polynomials in w1 as its coefficients. The
w2-nullclines are the line w2 = 0 and a subset of solutions
to another quadratic in w2, with coefficients independent
of w1. For the sake of brevity, the equations of nullclines
are given in Appendix A. For default parameter values
in Figure 3a, the nontrivial w2-nullcline has a shape of
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Figure 3: Behaviour of the long-timescale model (17), shown via (w1, w2) phase portraits and dynamic plots of example solutions, is excitable,
and remains excitable as individual parameters are varied. Plot (a) shows model behaviour for default parameter values (see Table 2). In
plots (b) and (c), tumour growth rate parameter α is varied, whereas effector death rate parameter δ is varied in plots (d) and (e), with other
parameters fixed at their default values in all plots. (w1, w2) phase portraits in upper panels are equipped with nullclines, steady states,
flow field (w˙1, w˙2) and an example solution trajectory. The latter, starting at w1(0) = 200, w2(0) = 300, is obtained numerically using the
same method as in Section 3.3. The time step between plotted trajectory points is uniform; points far apart indicate fast dynamics, whereas
points close together show slow dynamics. In lower panels the solution trajectory is plotted against time for 0 < t ≤ 36331. The red dotted
vertical line denotes the time, trelapse, at which tumour cell density, w2, exceeds 10 after the first shrinkage; trelapse increases when δ or α are
decreased.
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a rotated and skewed U that, together with the w2 = 0
line, resembles a cubic; this is intersected in different ways
by the w1-nullcline. The described nullcline geometry is
similar to that of the FN model, where a cubic nullcline of
one model variable is intersected by a straight line nullcline
of the other variable (Fitzhugh, 1961).
We investigate how robust nullclines and behaviour of
the system (17) are to small changes in individual param-
eter values. The U shape of the non-trivial w2-nullcline
is always preserved under changes in tumour kinetic con-
stants α (see Figures 3a to 3c) or β. Under variation of
parameters associated with the immune system and its re-
sponse to the tumour, the shape of the w1-nullcline ranges
from approximately linear, as in the FN model, to curved
(see Figures 3a, 3d and 3e); it intersects the w2-nullcline a
different number of times and in a number of ways, giving
variable numbers of steady states with a range of stability
behaviours. The shape of the w2-nullcline is therefore ro-
bust to parameter changes, whereas that of the w1-nullcline
is not.
Across all the plots in Figure 3, solution trajectories
exhibit excitable behaviour with large excursions in the
phase plane and switching kinetics. A typical trajectory
exhibits rapid vertical dynamics, during which the tumour
quickly grows or shrinks, until reaching the w2-nullcline.
It then moves on a slow timescale approximately horizon-
tally on this nullcline, with the number of effector cells
either slowly increasing or decreasing. When the horizon-
tal direction can no longer be sustained, the trajectory is
pushed onto a different branch of the w2-nullcline via fast
vertical movement. The rapid switches between nullcline
branches continue until a steady state or a stable limit
cycle is reached. We notice that the variability of the w1-
nullcline shape under single parameter variations does not
greatly impact the large excursions of trajectories in the
phase plane, but it does impact the long-term behaviour
as time progresses.
4.2. Separation of timescales and its implications
In Figure 3, we observe that the transient fast kinetics
arise due to the dominance of the vertical direction (0, w˙2)
in the flow field, except in the vicinity of the w2-nullcline
where w˙1 is significant, as in the FN model. This indicates
a separation of timescales in the model, whereby the w2
variable has a shorter timescale than the timescale of the
w1 variable. As parameters are varied, the length of time
trajectories spend moving on the w2-nullcline also varies.
The lower the pro-tumour/anti-immune parameters, such
as the rate of effector cell death/migration out of the tu-
mour region, δ, or tumour growth rate, α, the more time
passes until tumour relapse. While this indicates changes
in the difference of timescales as we vary the parameters,
and a degree of sensitivity of excitable solution trajectories,
small changes in individual parameters appear insufficient
for the system to lose its excitable nature. By systemati-
cally manipulating the parameters controlling the kinetics
of total effector cells, we will investigate the origin and
robustness of timescale separation in model (17), and the
associated fast-slow dynamics, one of our aims being to
identify parameter regimes in which excitable dynamics
are less pronounced.
Inspection of the default parameter values in Table 2
reveals that we can represent their sizes by writing each
of them as an O(1) parameter scaled with another appro-
priately sized parameter. We introduce two positive small
parameters, ζ = O(10−1) and ξ = O(10−3), which we
treat independently in order to preserve the richness of the
model when their values are close to zero. We relate them
to parameters from slow manifold equations (17) via
σ = ζσˆ, δ = ζδˆ, η = ηˆ/ζ, µ = ξµˆ, β = ξβˆ, (19)
noting that values of α and ρ are both O(1). We then
rewrite equations (17) as
w˙1 = ζ
(
σˆ + ρem
ηˆ + ζm − δˆe−
ξ
ζ
µˆem
)
=: ζg1(w1, w2),
(20a)
w˙2 = αm− κ2em− ξαβˆm2 =: g2(w1, w2), (20b)
where we drop the notation e = e†(w) and m = m†(w)
from (17) for simplicity.
Equations (20) are singular, and in the limiting case
0 < ξ < ζ  1 we can apply asymptotic methods, as in
Section 3, to accurately further approximate the fast and
slow dynamics. For reasons of brevity, we only sketch this
analysis here. By taking the limit ζ, ξ → 0, we approximate
the fast manifold equations for wF to leading order in ζ
and ξ via
w˙1,F = 0, (21a)
w˙2,F = αy†(wF)− κ2x†(wF)y†(wF). (21b)
From equations (21), we notice that the number of total
effector cells, w1,F, is approximately constant on the fast
manifold, while dynamics of total tumour cells, w2,F, are
governed by exponential-like terms, which emerge from the
difference between exponential growth of tumour cells and
their loss due to immune-induced death of tumour cells in
equation (3b) for m˙. We deduce that on the fast timescale
the total number of tumour cells diverges to infinity if
w1,F falls below the threshold value w×1 := ακ2 (1 +
ακ1w2
1+α ),
whereas the system is attracted to the tumour-free steady
state if w1,F > w×1 , i.e. enough effector cells are recruited
relative to the tumour size.
Once a trajectory that follows the fast manifold reaches
the neighbourhood of the w2-nullcline, it starts moving
on it, and we say it moves on the slow manifold of outer
equations (17). By rescaling time via τ˜ = τ/ζ in equations
(20), we obtain the following slow manifold equations for
wS with respect to τ˜ :
w˙1,S = g1(w1,S, w2,S), (22a)
g2(w1,S, w2,S) = 0, (22b)
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Figure 4: Dynamics of the long-timescale model (20), shown via (w1, w2) phase portraits, evolve from excitable to non-excitable as ζ increases
from 0.1 to 10; ζ is a dimensionless parameter that scales parameters associated with effector cells (see equation (19)). Large excursions in the
phase plane in plots (a) and (b) transform into regular oscillations in plot (c). The plots are generated using δˆ = σˆ = 3, while other parameters
are kept at their default values. Trajectories start at w1(0) = w2(0) = 200. See Figure 3 for legend.
where equation (22b) constrains the trajectory to the w2-
nullcline, i.e. the dynamics of w2,S are slave to those of
w1,S. In contrast to the asymptotic solutions derived in
Section 3, the trajectories here do not remain on the slow
manifold, but jump between the fast and slow manifolds.
When moving on the slow manifold, i.e. on a branch of
the w2-nullclines, the number of total effector cells changes
slowly, which eventually causes a change in the attracting
steady state of the fast manifold equations. The time point,
at which the threshold w×1 is hit, is approximately when
solution trajectories switch via fast dynamics to a different
branch of the w2-nullclines; see Figure 3. We conclude
that the separation of timescales and the logistic growth
assumption allow tumour cells to exploit small changes
in the effector cell numbers to rapidly expand to carrying
capacity in the parameter regime considered.
We show in Figure 4 how the system dynamics may
change from the excitable regime to a non-excitable one as
we increase the value of ζ. For smaller values of ζ, transi-
tions between the fast and slow manifolds are sharp, and
the trajectory moves on the above derived manifolds (see
Figure 4a). For larger values of ζ, the excitable dynamics
are less pronounced; they resemble classic oscillations, with
smaller excursions and periods of oscillation, and they do
not follow the nullclines closely (see Figure 4c). In this
case, the timescale of effector dynamics approaches those
of the tumour, rather than the tumour dominating and
the immune system slowly catching up, as in the excitable
regime.
In summary, our results show that the model’s excitable
behaviour can be attributed to a combination of the ro-
bust, cubic-like, shape of the w2-nullcline, the separation
of timescales, and the logistic growth assumption. Ex-
citability is observed for ζ as large as O(10−1), and we
have shown that a considerable inflation of the parameters
associated with the function of the immune system and
its response is needed to lose the excitable behaviour (see
Figures 3 and 4). We conclude that in the neighbourhood
of the default parameter regime the system (17) is inher-
ently prone to excitable behaviour, analogously to the FN
model.
5. Bifurcation analysis of slow dynamics
Having shown that the model can exhibit excitable
dynamics, we now investigate how parameter changes im-
pact the long-term behaviour. Our aim is to show that
system (17), or equivalently (18), captures immunoediting
behaviour and also a variety of other complex tumour-
immune dynamics. We first identify and characterise the
system’s steady states via asymptotic and linear stability
analysis. We then confirm and extend these results numer-
ically to describe the system’s global bifurcation structure
for different values of model parameters influencing effector
cell supply and decay, σ and δ. In the end we investigate
the sensitivity of the bifurcation structure to changes in
model parameters controlling tumour-effector cell inter-
actions, µ, ρ and η, in order to gain insight into tumour
responses to different immunotherapies, which may perturb
one or more of these model parameters depending on their
mechanism of action.
5.1. Characterisation of steady state solutions
Identifying the steady state solutions of the slow system
is most tractable when working with equations (18) for
variables e and m. Steady state solutions solve q(e,m) = 0
and are identical to steady state solutions of the full system
(3). We find that there is one tumour-free steady state
(e∗1, 0), with
e∗1 =
σ
δ
, (23)
and at most three nonzero-tumour steady states (e∗2,3,4,m∗2,3,4)
(physically realistic when both e∗ and m∗ are real and non-
negative) given by
e∗2,3,4 =
α
κ2
(1− βm) and m∗2,3,4 = m, (24)
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where m is a root of the cubic
p(m) := a3m3 + a2m2 + a1m+ a0 (25a)
with coefficients
a0 = η
(
σκ2
α − δ
)
,
a2 = −µ+ (µη + δ − ρ)β,
a1 = σκ2α + ρ− µη − δ + δηβ,
a3 = µβ.
(25b)
5.1.1. Asymptotic approximation of steady states
Recalling that µ and β are small for the default param-
eter values (see Table 2), we introduce the artificial small
parameter ξ = O(10−3) as before, and write µ = ξµˆ and
β = ξβˆ. This allows us to asymptotically approximate the
roots m of the cubic (25a), and obtain estimates for the
nonzero-tumour steady states (e∗2,3,4,m∗2,3,4). We detail
this analysis in Appendix B, and summarise the key results
here.
When 0 < ξ  1, there are at most three types of
steady state solutions:
(i) the tumour-free steady state (e∗1, 0) = (σδ , 0),
(ii) at most one intermediate-sized-tumour steady state
(e∗2,m∗2), where
e∗2 ∼
α
κ2
and m∗2 ∼ −
a0
aˆ1
(26)
are both O(1), and
(iii) at most two large-tumour steady states (e∗3,4,m∗3,4),
where
e∗3,4 ∼
α
κ2
(1− βˆmˆ3,4) and m∗3,4 ∼
1
ξ
mˆ3,4, (27a)
with mˆ3,4 =
−aˆ2 ±
√
aˆ22 − 4aˆ3aˆ1
2aˆ3
, (27b)
are O(1) and O(ξ−1) respectively.
The coefficients used above are all O(1), and given as
follows
aˆ1 =
σκ2
α
+ ρ− δ,
aˆ2 = −µˆ+ βˆ(δ − ρ),
aˆ3 = µˆβˆ.
(28)
In regions of parameter space where these steady states
are physically realistic and stable, we may identify them
with the elimination, equilibrium/dormancy and escape
phases that are associated with the three Es of immu-
noediting. To find these regions of the parameter space,
we study in Section 5.1.2 where the different steady states
are physically realistic, whereas we examine their stability
analytically in Section 5.1.3, and numerically in Section 5.2.
5.1.2. Physicality of steady states
Assuming that all model parameters are positive, we
observe that the tumour-free steady state (σδ , 0) exists for
all positive values of σ and δ. From (26) we deduce that
the intermediate-sized-tumour steady state is nonnegative
if
δ(σ, α, κ2) ≤ δ < ρ+ δ(σ, α, κ2), (29)
where δ(σ, α, κ2) :=
σκ2
δ
, (30)
or equivalently a0η ≤ 0 < aˆ1. We use (27) to derive similar
conditions for the large-tumour steady states; details are
provided in Appendix B. In short, provided mˆ3,4 ≤ β−1,
there is a unique large-tumour steady state solution (e∗3,m∗3)
when aˆ1 < 0, two such solutions when 0 < aˆ1 < aˆ22/4aˆ3 =:
aˆ# and aˆ2 < 0, and none otherwise.
In Figure 5 we plot the borders of the asymptotic physi-
cally realistic regions in the (σ, δ) plane, and compare them
to a colour plot of the (σ, δ) plane, which shows how the
number of physically realistic steady states varies in this
parameter space. The line a0 = 0 accurately captures the
lower border of the region, in which the intermediate-sized-
tumour steady state is physically realistic, while the curve
aˆ1 = 0 only qualitatively captures the upper border of
this region. The border aˆ1 = aˆ#1 , where the asymptotic
large-tumour steady states (e∗3,m∗3) and (e∗4,m∗4) collide
and become complex conjugates, shows similar inaccura-
cies (see Figure 5). These discrepancies occur because our
asymptotic approximations of the nonzero-tumour steady
states, given in Section 5.1.1, lose accuracy in the neigh-
bourhood of parameter regimes where the roots of the cubic
(25a) collide, e.g. as the parameters approach the curve
aˆ1 = 0.
To avoid these difficulties, we study the multiplicity of
roots of the original cubic (25a). We identify parameter
sets for which multiplicity of the cubic roots changes by
considering the discriminant,
∆ := a22a21 − 4a3a31 − 4a32a0 − 27a23a20 + 18a3a2a1a0, (31)
of the cubic (25a). Using Mathematica we numerically
compute curves in (σ, δ) parameter space on which ∆ =
0. These curves separate regions which have different
numbers of physically realistic steady state solutions (see
Figure 5). At the lower boundary of the dark green region,
roots m∗3 and m∗4 collide and become complex, while this
occurs for roots m∗2 and m∗4 at the upper boundary of
the dark green region, as mentioned previously. On the
black dotted curve in the light purple region, the complex
roots m∗2 and m∗4 collide again and become real, but since
they are real and negative (unrealistic), the steady state
multiplicity does not change there. Accurately computing
curves on which steady states coalesce is important, since
they indicate parameter regimes where saddle-node-type
bifurcations occur, i.e. when there is a collision of two
physically realistic steady states, one stable, and the other
a saddle; we demonstrate this in Sections 5.2 and 5.3.
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Figure 5: The number of physically realistic steady states in system (18) changes as model parameters vary. Accordingly, (σ, δ) parameter
space is decomposed into distinct regions which are colour-coded in line with the number of physically realistic steady states that exist. The
plot is generated by numerically computing the number of physically realistic steady states of system (18) at different values of σ and δ that lie
on a triangular mesh of the (σ, δ) plane, with other parameters fixed at their default values (see Table 2). We also plot analytically obtained
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aˆ1 = 0 and aˆ1 = aˆ#1 , capture them only qualitatively.
5.1.3. Linear stability of steady states
To demonstrate the system exhibits immunoediting
behaviour via the three types of steady states identified
in Section 5.1.1, our goal in this section is to identify
parameter regions in which each steady state is both stable
and physically realistic.
We determine steady state stability via linear stability
analysis, complemented with numerics. As in Section 5.1.1,
we assume throughout that parameters µ and β scale with
the small parameter 0 < ξ  1. We introduce a second
small parameter 0 < ν  ξ, and seek solutions of the form
e(τ) = e∗ + νe1(τ) +O(ν2), (32a)
m(τ) = m∗ + νm1(τ) +O(ν2), (32b)
where (e∗,m∗) are steady states. By substituting (32)
into equations (18), equating terms of O(ν) to zero and
neglecting terms of O(ξ) or higher orders of ν, we obtain a
linearised system x˙ = J (e∗,m∗)x for x = (e1,m1), with
J (e∗,m∗) =[
1 + κ1m∗ κ1e∗
κ2m
∗ 1 + κ2e∗
]
︸ ︷︷ ︸
=:B(e∗,m∗)
−1 [ ρm∗
η+m∗ − δ ρηe
∗
(η+m∗)2
−κ2m∗ α− κ2e∗
]
︸ ︷︷ ︸
=:A(e∗,m∗)
(33)
as the Jacobian, and (e∗,m∗) as the steady state asymp-
totic approximation to leading order in ξ, such as given
in Section 5.1.1. The eigenvalues λ1 and λ2 of J (e∗,m∗)
predict exponentially decaying behaviour of the linearised
system, and therefore linear stability of the steady state
(e∗,m∗) whenever the condition maxi=1,2 Re(λi) < 0 is
satisfied.
For the tumour-free steady state (e∗1,m∗1) = (σδ , 0)
λ1 = −δ and λ2 = α− σκ2
δ
, (34)
so this steady state is linearly stable when the parameters
satisfy
δ <
σκ2
α
= δ(σ, α, κ2), (35)
This means that the ratio of the basal effector influx rate,
σ, and effector death rate, δ, must be larger than the net
tumour growth rate, α, for the tumour-free steady state to
be stable, i.e. for tumour eradication.
Considering (29) and (35), we observe that the region in
which the intermediate-sized-tumour steady state (e∗2,m∗2)
is physically realistic is separated from the region in which
the tumour-free steady state is stable by the line δ =
δ(σ, α, κ2). This implies that the tumour-free and the
intermediate-sized-tumour steady states may undergo a
transcritical bifurcation when δ = δ(σ, α, κ2), provided
the intermediate-sized-tumour steady state is stable once
it has emerged as physically realistic.
When characterising the local stability of the intermediate-
sized-tumour steady state, we consider the trace and the
determinant of the Jacobian evaluated at this steady state.
We note that
det(J (e∗,m∗)) = det(A(e
∗,m∗))
det(B(e∗,m∗)) , (36)
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and
tr(J (e∗,m∗)) = tr(B˜(e
∗,m∗)A(e∗,m∗))
det(B(e∗,m∗)) , (37)
where B˜(e∗,m∗) = det(B(e∗,m∗))(B(e∗,m∗))−1, and
det(B(e∗,m∗)) = 1 +κ2e∗+κ1m∗ > 0 for any nonnegative
steady state. Therefore, the signs of det(J (e∗,m∗)) and
tr(J (e∗,m∗)) are determined by the signs of det(A(e∗,m∗))
and tr(B˜(e∗,m∗)A(e∗,m∗)) respectively. When (e∗,m∗) =
(e∗2,m∗2) from (26), we have
det(A(e∗2,m∗2)) =
α
ηρ
(σκ2
α
− δ + ρ
)2
m∗2 (38)
which is positive when m∗2 is physically realistic. Stability
of (e∗2,m∗2) thus reduces to satisfying the trace condition
tr(B˜(e∗2,m∗2)A(e∗2,m∗2)) =
− αη
(
σκ2
α − δ
)
aˆ1
(
κ1 − 1
ηρ
aˆ21
)
− (α+ 1)σκ2
α
< 0.
(39)
We conclude that in regions, where δ > δ(σ, α, κ2) and in-
equality (39) are simultaneously satisfied, the intermediate-
sized-tumour steady state is stable.
When δ = δ(σ, α, κ2),
tr(B˜(e∗2,m∗2)A(e∗2,m∗2)) = −(α+ 1)
σκ2
α
< 0, (40)
so our analysis predicts that the tumour-free and the inter-
mediate-sized-tumour steady states undergo a transcritical
bifurcation on this curve. Moreover, when tr(B˜(e∗2,m∗2)
A(e∗2,m∗2)) = 0, the Jacobian eigenvalues are purely imag-
inary, and the intermediate-sized-tumour steady state is
predicted to undergo a Hopf bifurcation. We numerically
validate these predictions in Section 5.2, and note that
further work is required to demonstrate existence of the
Hopf bifurcation.
Since exact analytical expressions for the roots of the
cubic (25a) are not practical to work with, we have only
characterised the stability of nonzero-tumour steady states
using their asymptotic approximations (26) and (27), as
shown above for the intermediate-sized-tumour steady state.
Similar analysis for the large-tumour steady states is diffi-
cult due to the complexity of the asymptotic expressions
(27) (see Appendix B). Therefore, in Section 5.2, we nu-
merically identify parameter regimes in which these steady
states are stable.
5.2. Bifurcation structure for default parameter values as
the basal effector supply rate varies
Our aims here are to use numerical methods to validate
analytical results from Section 5.1, and to detect global
bifurcations not evident from the linear stability analysis.
We focus on σ, the nondimensional constant supply rate of
effector cells, as the key bifurcation parameter. A larger
value of σ means the immune system is more effective in
recruiting effector cells into the tumour microenvironment,
and the recruited cells better infiltrate the tumour. In
practice, σ is expected to vary between patients since those
properties of the immune system on which this parameter
depends on, such as the specificity of the repertoire of effec-
tor cells and the degree of their infiltration of the tumour,
exhibit high inter-patient variability (Fridman et al., 2012;
Rosenthal et al., 2019). The parameter σ may also vary
in response to immunotherapies, such as vaccination and
adoptive T cell therapy, both of which provide an exter-
nal boost to the immune system (Farkona et al., 2016).
These two therapies enhance the population of tumour
antigen specific effector T cells, by increasing exposure to
tumour antigens away from the tumour microenvironment
described by our system (e.g. in lymph nodes or ex vivo).
The system’s bifurcation structure is depicted with
bifurcation diagrams showing how (scaled) steady state
tumour and effector cell numbers vary with σ (see Figure
6). We generate these diagrams numerically, by considering
discrete values of σ that lie in the interval [0, 1], while fixing
other parameters at their default values (see Table 2). We
calculate for each value of σ the steady states of system
(18), and their corresponding eigenvalues and eigenvectors
to characterise local stability. Moreover, by perturbing a
steady state along the direction of an eigenvector associ-
ated with a positive/negative eigenvalue, and using the per-
turbed point as an initial state for forward/backward inte-
gration of equations (18), we also generate unstable/stable
manifolds of the computed steady states. We plot the
steady states and manifolds in (w1, w2) phase portraits at
different values of σ (see Figure 8 and Figure D.1), and
observe that in some regions of parameter space the phase
portraits exhibit limit cycles. By tracing where limit cycles
emerge and where steady states change multiplicity or sta-
bility as σ varies, we identify five regions with qualitatively
different model behaviour, separated by four bifurcation
points σSH, σHopf , σSO and σT (see schematic in Figure 7).
The behaviours in the five regions (A)–(E) are described
below:
(A) 0 < σ < σSH: The system is monostable; for all
positive initial conditions trajectories evolve to the
larger of the large-tumour steady states (tumour es-
cape). There are also three unstable steady states;
the tumour-free and the smaller of the large-tumour
steady states are saddles, linked via a heteroclinic
connection (see Figures D.1A and 8A).
(AB) σ = σSH: The large-tumour steady states collide at a
saddle-node homoclinic bifurcation (or infinite period
bifurcation) (Nekorkin, 2015); the saddle and node
annihilate each other, and the tumour-free steady
state admits a large-amplitude, stable homoclinic
orbit.
(B) σSH < σ < σHopf : For all positive initial conditions
trajectories evolve to the stable homoclinic orbit as-
sociated with the tumour-free steady state, via os-
cillations with large amplitudes (see Figures D.1B
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and 8B).
(BC) σ = σHopf : There is a subcritical Hopf bifurcation,
at which the intermediate-sized-tumour steady state
becomes stable and is surrounded by an unstable,
small-amplitude limit cycle that emerges from it.
(C) σHopf < σ < σSO: The system exhibits bistability
between the intermediate-sized-tumour steady state
and the homoclinic orbit; trajectories starting within
the region of the phase space mapped out by the un-
stable, small-amplitude limit cycle, oscillate towards
the intermediate-sized-tumour steady state (tumour
dormancy); otherwise the system evolves towards the
homoclinic orbit via large-amplitude oscillations (see
Figures D.1C and 8C).
(CD) σ = σSO: There is a saddle-node of limit cycles
(Nekorkin, 2015), at which the stable homoclinic and
the unstable Hopf orbits collide, and then annihilate
each other.
(D) σSO < σ < σT: The system is monostable; trajec-
tories evolve towards the stable intermediate-sized-
tumour steady state (tumour dormancy) via damped
oscillations, possibly preceded by a large excursion
(see Figures D.1D and 8D).
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Figure 6: The long-timescale system (18) (or equivalently (17)) exhibits the three Es of immunoediting through stable steady states of varying
tumour cell densities. We can see this in the bifurcation diagrams, which are obtained numerically by sweeping through the σ parameter space,
and computing the system steady states and their stability at discrete values of σ between 0 and 1. Other parameters are fixed at their default
values (see Table 2). Plots (a) and (b) respectively show the steady state numbers of free effector and tumour cells. Purple and green curves
denote large-tumour steady states, blue curves denote intermediate-sized-tumour steady states, and orange curves denote tumour-free steady
states. Local stability of steady state is distinguished by linestyle, whereby solid curves denote stable solutions, while dashed curves denote
unstable ones. Black points mark bifurcations of steady state solutions, i.e. where solution branches change stability or collide.
A B C D E
σ
m∗
σSH σHopf σSO σT
0
Figure 7: Schematic (not to scale) of the bifurcation diagram for scaled tumour cell numbers in Figure 6b, indicating how periodic solutions
arise in the long-timescale system (17) with respect to its steady states, as the parameter σ is varied. Black curves indicate tumour cell
numbers of steady state solutions, whereas blue curves indicate maximum and minimum tumour cell numbers of periodic solutions. Local
stability of solutions is distinguished by linestyle, whereby solid curves denote stable solutions, while dashed curves denote unstable ones. As σ
is increased, the system undergoes the following bifurcations: SH = saddle-node homoclinic bifurcation, Hopf = subcritical Hopf bifurcation,
SO = saddle-node of orbits, T = transcritical bifurcation. Bifurcations of steady state solutions are denoted with black dots, while bifurcations
of periodic solutions are denoted with dotted vertical lines. These bifurcations split the parameter space into regions of qualitatively different
model behaviours with respect to its steady states and orbits; the different regions are shaded with grey of varying intensities.
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(E) σ > σT
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Figure 8: As σ is varied in Regions (A)–(E) of the parameter space (see the schematic in Figure 7), phase portrait plots (A)–(E) of the
long-timescale model (17) in (w1, w2) plane reveal that the model exhibits rich bifurcating behaviours, which include emergence of orbits and
large excursions in phase space. The values of σ for which the phase portraits are generated lie within intervals indicated in respective plot
captions, while other parameters are fixed at their default values (see Table 2). The lower panel plots show model behaviour in the vicinity of
the tumour-free steady state by magnifying this area of phase space. Solid black curves show forward integrated trajectories (stable), whereas
solid orange curves denote trajectories integrated backward in time (unstable) in order to uncover the dynamics close to unstable orbits. For
schematics of these phase portrait plots, see Appendix D.
(DE) σ = σT: There is a transcritical bifurcation, at which
the unstable tumour-free and the stable intermediate-
sized-tumour steady state exchange stability, and
the latter steady state becomes physically unrealistic
(negative).
(E) σ > σT: The system is monostable; all trajectories
evolve to the tumour-free steady state (tumour elim-
ination). (See Figures D.1E and 8E)
The local bifurcations established numerically agree with
the analytical predictions from Section 5.1. Further work
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is needed mathematically to show existence of the iden-
tified global bifurcations, and the local subcritical Hopf
bifurcation (e.g. weakly nonlinear analysis); such analyses
are beyond the aim and scope of this paper.
We have shown how the system dynamics change as
the basal supply rate of effector cells, σ, and thereby the
strength of the immune system, is increased. When σ is
small (in Region (A)), effector cells at sufficient numbers in-
filtrate tumours and decrease their volume, but the response
cannot be sustained; tumour escape eventually occurs for
all tumours. In Region (B) effector cells infiltrate all tu-
mours, and markedly decrease their size. As this happens,
effector cell numbers also decline, enabling the immune-
suppressed tumour to relapse and rapidly grow towards its
carrying capacity until the immune system is stimulated
again. In this way, the cycle repeats, with tumour and
effector cells oscillating in an excitable manner as they
traverse phase space in the vicinity of the large-amplitude
homoclinic orbit, passing through regions with very small
and large tumour mass. Increasing σ further (Region (C))
leads to the emergence of a small region of phase space,
in which the immune system controls the tumour size –
tumour equilibrium or dormancy. In Region (C) there
is a fine balance between tumour and effector cell num-
bers, and all solutions starting within it oscillate towards
the dormant steady state as the amplitude of oscillations
decreases. In order to enter this dormant region, the tu-
mour must be suppressed in a specific way, since otherwise,
the system is attracted to the homoclinic loop of escape
and elimination, and we say that the tumour is “sneaking
through”. As σ increases, the basin of attraction of the
small tumour steady state increases so that in Region (D),
the immune response is strong enough to drive all tumours
to a dormant state, albeit after a large phase-plane excur-
sion (see Figure 8D). Ideally, we would seek to increase σ
(e.g. via therapy) so that the system enters Region (E),
where the model predicts all tumours will be eradicated by
the immune system.
Taken together, our results suggest that, as model pa-
rameters vary, the system exhibits the three Es of im-
munoediting – elimination, equilibrium and escape. Our
analysis reveals that a therapy, which increases the basal
effector supply rate (e.g. adoptive cell therapy or can-
cer vaccine), could push the system from tumour escape
to elimination or equilibrium at the intermediate-sized-
tumour steady state. Such changes in system behaviour
occur via a series of local bifurcations (saddle-node, Hopf
and transcritical).
The system also admits stable oscillatory solutions with
large excursions in the phase plane, arising from its intrin-
sic excitability (see Section 4). We have shown numerically
that these solutions emerge and disappear via global bifur-
cations of a homoclinic orbit, a feature that is common in
excitable systems, but cannot be detected via local analysis.
The excitable homoclinic orbit is seen as the main driver
of excitable dynamics in all regions, as large excursions are
observed not only in regions where the orbit exists, but
also in other regions (see Figures D.1 and 8), where the
associated (disconnected) steady state manifolds retain the
approximate shape of the orbit.
5.3. Changes in the bifurcation structure as default param-
eters vary
We now consider how variation of other model param-
eters affects the bifurcation structure. We focus on the
parameters µ, ρ and η, which together determine the ex-
tent of the immune response to the tumour. This is be-
cause they may be altered by immunotherapies that impact
tumour-immune interactions directly, or reverse the effects
of tumour-modulated immunosuppression; for example, im-
mune checkpoint therapies that inhibit the PD-1/PD-L1
axis may, in a tumour-dependent manner, decrease T cell
apoptosis, exhaustion and anergy, while also increase T
cell proliferation (He et al., 2015). At the same time, we
investigate the efficacy of such treatments across popula-
tions of patients whose immune systems (in the absence
of a tumour) can vary in strength; a patient might have a
compromised immune system (corresponding a small σ or a
large effector death rate δ); they may have been vaccinated
or undergone adoptive cell therapy (large σ).
Region
No.
Denotation in (σ, δ) parameter
space of Fig. 9 and the left
panels of Figs. 10, 11 and E.1
Description in Sec. 5.2
and phase portrait in
Fig. 8
Qualitative behaviour
(1) yellow with diagonal lines (E) elimination
(2) yellow with cross-hatching joint (C) and (D) equilibrium (or oscillations – bistable)∗
(3) orange (B) oscillations
(4) yellow below upper curve ∆ = 0 (A) escape
(5) yellow above upper curve ∆ = 0 ∗∗ escape
(6) blue with diagonal lines ∗∗ escape or elimination – bistable
(7) blue with cross-hatching ∗∗ escape or equilibrium – bistable
Table 3: Distinct regions of (σ, δ) parameter space, as denoted with different colours and hatching (see the second column) in Figure 9 and in
the left-panel plots of Figures 10, 11 and E.1, exhibit different qualitative behaviours that range from elimination to escape (see the fourth
column). The third column indicates which regions from the bifurcation schematic in Figure 7, where only σ varies, some regions of the (σ, δ)
parameter space in Figure 9 correspond to. ∗Region (2) exhibits two distinct qualitative behaviours, and should be split into two disjoint
parameter subregions depending on whether the stable homoclinic orbit with large amplitude and period exists. In the parameter subregion
where this orbit exists, trajectories may evolve to an oscillatory solution in the vicinity of the orbit. ∗∗For a description of model behaviour in
Regions (5)–(7) see Section 5.3.1. Phase portraits for these regions are omitted for brevity.
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Figure 9: The long-timescale model (17) exhibits qualitatively different behaviours as parameters σ and δ are varied, and the model undergoes
bifurcations. The plot illustrates this by showing how (σ, δ) parameter space is split into distinct regions depending on existence and stability
of model’s steady states. Regions with different numbers of stable steady states are distinguished using a colour map. It is generated by
numerically computing the number of stable steady states of system (18) at discrete values of σ and δ that lie on a triangular mesh of (σ, δ)
plane, with other parameters fixed at their default values (see Table 2). Boundaries of distinct regions are traced by different curves on which
bifurcations may occur. Dotted black curves are numerically computed curves satisfying ∆ = 0, and therefore indicate where the multiplicity
of steady states changes (see Section 5.1.2). Dashed black lines indicate where the tumour-free steady state changes its local stability and
intermediate-sized-tumour steady state becomes physically unrealistic, i.e. when δ = δ(σ, α, κ2). Solid grey lines indicate where the local
stability of the latter steady state changes, i.e. when tr(J (e∗2,m∗2)) = 0 (see Section 5.1.3). Dashed grey curves, for example by the transition
between Regions (3) and (5) for large δ, indicate where a large-tumour steady state of O(ξ−1), with 0 < ξ  1 (as in Section 5.1.1), changes
stability; in analysis not presented in this paper we derive that this is given by the curve p((2β)−1) = 0, where p is the cubic (25a). Hatching
with diagonal lines and grey cross-hatching (between solid grey and dashed black lines, see the magnified area in the plot) respectively denote
regions in which the tumour-free and intermediate-sized-tumour steady states are locally stable. The red horizontal line marks the default
value of δ, δ0 = 0.374 (see Figures 6 and 7 for bifurcation diagrams at this value of δ).
5.3.1. Varying σ and δ
We first study the bifurcation structure when σ and
δ co-vary in a neighbourhood of the default parameter
regime. This provides a reference for benchmarking model
outcomes associated with variation of parameters linked
to immunotherapy. We numerically track the number of
physically realistic steady states, and their (local) stabil-
ity, in order to partition the (σ, δ) plane (see Figure 9);
transitions from one region to another indicate qualitative
changes in the system dynamics. Using analytical results
from Section 5.1, we also compute curves, on which the
existence and stability of steady state solutions change.
In the (σ, δ) plane, these curves are in good agreement
with the numerically determined region boundaries. This
confirms our analysis and increases our insight into the
behaviour of our model. We identify seven distinct regions
listed in Table 3. Regions (1)–(4) exhibit behaviours equiv-
alent to those in Regions (A)–(E), as related in Table 3,
and described in both Section 5.2 and Figure 7. Behaviours
in Regions (5)–(7) are described as follows:
(5) The system is monostable; for all positive initial
conditions trajectories evolve to the large-tumour
steady state (tumour escape). The only other steady
state is the tumour-free one, which is a saddle.
(6) The system exhibits bistability between the tumour-
free steady state (tumour elimination) and the larger
of the large-tumour steady states (tumour escape);
depending on initial conditions trajectories evolve to
one of these two stable steady states. The smaller of
the large-tumour steady states is a saddle.
(7) The system exhibits bistability between the inter-
mediate-sized-tumour steady state (tumour equilib-
rium) and the larger of the large-tumour steady states
(tumour escape). The smaller of the large-tumour
steady states and the tumour-free steady state are
both saddles.
In Figure 9 we see that varying δ typically has a similar
effect to varying σ. The model predicts that therapies
that increase σ and/or decrease δ can drive the system to
regions of parameter space where tumour elimination or
dormancy occur for all initial conditions (Region (1) and a
subregion of Region (2) respectively).
We now investigate how varying the tumour-immune
interactions parameters, µ, ρ and η, affects model behaviour
in (σ, δ) parameter space.
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5.3.2. Varying ρ
As ρ, the tumour-stimulated supply rate of effector cells,
decreases, we observe in panel (iii) of Figure 10 an increase
in the region in which a locally stable large-tumour steady
state exists; tumour cell numbers of this steady state de-
crease as σ increases, and its confluence with the saddle
large-tumour steady state occurs at a larger value of σ.
The distinction among the nonzero-tumour steady states
(see Section 5.1.1) is blurred for smaller values of ρ, and
eventually one nonzero-tumour steady state is lost (e.g. at
ρ = 0.01, see panels (i) and (iii) of Figure 10). This is
supported by our asymptotic results (see Section 5.1.2),
which predict that the region given by (29), in which the
intermediate-sized-tumour steady state is physically realis-
tic, will shrink as ρ is reduced.
When ρ is small, the presence of tumour cells does not
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(b) ρ = ρ0/22.6 = 0.5
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(c) ρ = 1.33ρ0 = 1.5
Figure 10: Series of plots (a)–(c) showing how the bifurcation structure of the long-timescale system (17) changes as ρ is varied from its default
value ρ0 = 1.131. As ρ is increased, Regions (4)–(6) in which the model may exhibit tumour escape shrink, due to which Region (1) with
tumour elimination expands up to its maximum size below the black dashed line, δ = δ(σ, α, κ2). Above this line, while small regions in which
tumour dormancy may occur (Regions (2) and (7)) emerge, the dominating region is Region (3) in which the model exhibits large-amplitude
oscillations. For each value of ρ, we present three bifurcation diagrams: plots of (σ, δ) parameter space showing (i) regions with different
numbers of physically realistic steady states (see Figure 5 for legend and details), and (ii) regions with different numbers of stable steady states
(see Figure 9 for legend and details); (iii) bifurcation diagrams of tumour steady state numbers, m∗, as σ is varied and δ is fixed at its default
value (see Figure 6 for legend and details).
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(a) η = η0/50 = 0.404
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(b) η = 2η0 = 40.38
Figure 11: Series of plots (a) and (b) showing how the bifurcation structure of the long-timescale system (17) changes as η is varied from its
default value η0 = 20.19. As η is decreased, Regions (2) and (7) in which the dormant steady state of system (17) is locally stable expand. For
each value of η, we present three bifurcation diagrams: plots of (σ, δ) parameter space showing (i) regions with different numbers of physically
realistic steady states (see Figure 5 for legend and details), and (ii) regions with different numbers of stable steady states (see Figure 9 for
legend and details); (iii) bifurcation diagrams of tumour steady state numbers, m∗, as σ is varied and δ is fixed at its default value (see
Figure 6 for legend and details).
stimulate effector cells and their proliferation sufficiently to
eliminate or control the tumour, e.g. due to low tumour im-
munogenicity or immunosuppression. We see that, within
the plotted (σ, δ) parameter region, decreasing ρ shrinks
Regions (2) and (7) in which the intermediate-sized-tumour
steady state is mono- or bistable, and dormancy may occur
(see panels (ii) and (iii) of Figure 10). Since the fraction
of the (σ, δ) parameter space with a locally stable large-
tumour steady state (Regions (4)–(6)) increases, Region (1)
exhibiting tumour elimination contracts, while Region (6)
with bistability of escape and elimination expands.
Conversely, by increasing ρ, effector cells may increase
their numbers at a greater rate in response to the tumour,
and eradicate it more effectively. Therefore, as ρ increases,
there is a reduction in Regions (4)–(6) in which tumour
escape may occur. Region (1) with elimination thus ex-
pands, but only up to its maximum size below the line
δ = δ(σ, α, κ2) (see Section 5.1.1). Above this line, Re-
gion (3) with stable, large-amplitude, oscillatory solutions
is considerably magnified. While Regions (2) and (7) in
which tumour dormancy may occur also appear, these are
small, and large-amplitude oscillations or escape are the
dominant behaviour (see panel (ii) of Figure 10c).
5.3.3. Varying µ
Increasing µ, the rate of effector cell inactivation, has
a similar effect on model behaviour as decreasing ρ, but
with greater sensitivity (see Appendix E). This is expected
since the term ρemη+m in model equations (3) may saturate,
whereas the related term −µem does not.
5.3.4. Varying η
Changes in parameter η, which determines the size of
the tumour at which effector proliferation starts saturating,
have a different effect on the model dynamics compared
to changes in either ρ or µ. Varying η mainly affects the
zero-trace/Hopf bifurcation curve (solid grey), where the
intermediate-sized-tumour steady state changes stability
(see Figure 11). Decreasing η therefore increases the size
of Regions (2) and (7) that exhibit mono- and bistability
of tumour dormancy, respectively, and reduces the size of
Region (3) with stable oscillatory solutions. We conclude
that a therapy, which reduces η (i.e. increases the threshold
at which limitations in immune response start to occur),
may push the system to a region where tumour dormancy
is possible; due to the prospect of region bistability this
may hold only for a subset of the phase space.
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5.3.5. Summary
We observe that in (σ, δ) parameter space the line
δ = δ(σ, α, κ2), which is only affected by changes in the
tumour growth rate, α, or the scaling parameter, κ2, strati-
fies patients with parameters in (σ, δ) parameter space into
those with strong immune responses (immunocompetent
or vaccinated), whose tumours may be eliminated, and
those with weaker responses (immunocompromised), whose
tumours may at best be controlled. Assuming that the
immune state of the patient, characterised by parameters
σ and δ, is fixed, we note that changing parameters ρ and
µ separately or simultaneously is beneficial for immuno-
competent patients. For immunocompromised patients,
manipulating η is more effective, as it is possible to achieve
tumour dormancy. Ultimately, to achieve tumour elimina-
tion for immunocompromised patients, the basal function
of the immune system must be improved, for example by
targetting the parameters σ and/or δ.
6. Discussion and conclusions
We investigated a five-compartment mathematical model
by Kuznetsov et al. (1994) to increase understanding of
the impact that nonlinear relations between tumour and
effector (immune) cells in the tumour microenvironment
have on tumour growth dynamics. We performed a new
asymptotic reduction of the model and characterised its
behaviour. In particular, we systematically studied the
model’s sensitivity to changes in parameter values in or-
der to understand how the efficacy of the immune system
and its response to the tumour affect tumour growth. We
showed further that the model is excitable, which would be
a notable feature of tumour-immune interactions, and re-
vealed how this can give rise to complex dynamic behaviour
not reported in analyses of alternative simplifications of
Kuznetsov et al.’s model.
In Kuznetsov et al.’s original model a separation of
timescales occurs due to differences in the rates of con-
jugate formation and dissociation without further effect
and all remaining processes. Exploiting this to introduce a
small parameter, we derived a two-dimensional matched
asymptotic approximation that is more accurate in this
distinguished limit than the original quasi-steady-state ap-
proximation (QSSA) proposed by Kuznetsov et al. (1994)
(see Appendix C). On the short timescale, the numbers of
total tumour and total effector cells do not vary at leading
order, while conjugates relax to a steady state. This allows
for simplification of the full model on the long timescale,
where conjugates react instantenously to changes in to-
tal effector and total tumour cell numbers, and so vary
parametrically with respect to these variables at leading
order. The accuracy of the asymptotically reduced model
was compared numerically with the full model on both
timescales and in multiple parameter regimes, and shown
to preserve its excitable and bifurcating dynamics, unlike
the QSSA model. This result highlights that special care is
needed when applying the quasi-steady-state assumption.
We note that parameter estimates for the rate of conjugate
dynamics are needed in order to justify our asymptotic
reduction; this may in future motivate the exploration of al-
ternative distinguished limits of Kuznetsov et al.’s original
model.
On the long-timescale, in a neighbourhood of the default
parameter regime, the tumour-immune dynamics of our
reduced model are excitable due to the nullcline structure
and the large ratio of timescales. Excitability manifests
through large phase-plane excursions; these are charac-
terised by alternation between short periods of large and
rapid changes in total tumour cell numbers, and long peri-
ods of slow variation in total effector cell numbers, during
which tumour cell numbers remain close to zero or the
carrying capacity. The switch from slow to fast dynamics is
driven by exponential growth of the tumour when effector
cell numbers are much smaller than tumour cell numbers.
This model feature illustrates how the underlying saturat-
ing growth, as modelled by logistic growth dynamics in this
context, may contribute to excitability. It also provides a
possible explanation for why tumours often return after
periods of remission in clinic. Long-term tumour recurrence
is exhibited in the model through long time periods with
low tumour cell numbers, followed by rapid (exponential)
tumour regrowth. We note that the length of the tumour
remission period under small parameter changes varies con-
siderably, which suggests our excitable model is sensitive
to parameters at small cell numbers. In future work, we
will therefore investigate how stochastic effects impact the
excitable model dynamics, focusing on regimes when cell
numbers are small.
Like Kuznetsov et al.’s QSSA model, our reduced model
exhibits the three Es of immunoediting – elimination, equi-
librium, and escape (Dunn et al., 2004). We investigated
how the number and nature of steady state and limit cycle
solutions change as we vary σ, the basal rate at which effec-
tor cells are introduced to the tumour microenvironment,
and δ, their death rate, in order to identify parameter
regions in which each stage of immunoediting arises via a
(locally) stable steady state. For large σ and small δ (im-
munocompetent or vaccinated patient), tumour elimination
is predicted. For small σ and large δ (immunocompromised
patient), the tumours escape immune surveillance (and
grow to carrying capacity). For intermediate values of σ
and δ, the tumour responses are predicted to be diverse;
bistability of the tumour elimination/equilibrium and es-
cape solutions can occur; monostability of a homoclinic
orbit with a large amplitude, or bistability of the latter
with the tumour equilibrium solution can also arise. We
conclude that inter-subject variability in immune function,
particularly in the supply and death rates of effector cells,
or in the initial numbers of tumour and effector cells, can
result in large qualitative differences in how a particular
tumour progresses. Experiments have indicated similar
qualitative dichotomies in tumour progression curves be-
tween subjects that respond to cancer therapy, and those
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that do not, examples being preclinical mouse studies test-
ing the efficacy of immune checkpoint inhibitors of the
PD-1/PD-L1 axis in combination with a Bruton’s tyrosine
kinase inhibitor (Sagiv-Barfi et al., 2015) or with radiother-
apy (Dovedi et al., 2017). Variability in parameters and
variability in initial cell numbers represent two different
hypotheses via which our model may explain inter-subject
heterogeneity of tumour responses observed experimentally.
Our analysis has shown that the intrinsic excitability of
the model generates a complex, non-intuitive, bifurcation
structure that includes emergence of a homoclinic orbit.
Model solutions traversing the vicinity of this orbit un-
dergo long-term oscillations that demonstrate long-term
tumour reccurence. Short-term oscillations, as also ob-
served in leukemias (Mehta and Agarwal, 1980; Rodriguez
and Lutcher, 1976; Gatti et al., 1973), can also be observed
in the model’s excitable parameter regime and away from
it; here the system may evolve via damped oscillations to a
nonzero-tumour steady state or to a limit cycle with smaller
periods and amplitudes than for the large homoclinic orbit.
While no limit cycle solutions, only damped oscillatory
steady state solutions, exist in the QSSA model proposed
by Kuznetsov et al. (1994), long- and short-term oscillatory
behaviour of the type presented in this paper was observed
in a model developed by Kirschner and Panetta (1998) to
describe interactions of cancer and immune cells in the
presence of interleukin-2, a cytokine inducing effector cell
proliferation. We note further that in parameter regimes
where the homoclinic orbit and the equilibrium steady state
solution are bistable, our reduced model exhibits sneaking
through, whereby very small tumours may escape (in the
vicinity of the orbit) while larger ones may be controlled,
and, counter-intuitively, immunostimulation can be damag-
ing. In Kuznetsov et al.’s QSSA model these phenomena
were shown to depend on the rate of effector cell inacti-
vation, µ, while in our model they are attributed to the
model’s excitable properties. Overall, having demonstrated
that our reduced model is consistent with a range of clin-
ically observed phenomena, we postulate that excitable
dynamics may underpin tumour-immune interactions.
By varying parameters that regulate the dynamics of
the effector cells, we used our model to investigate how
tumour cell numbers may be controlled via immunotherapy
in a heterogeneous population of patients. As previously
suggested, immunotherapies that improve competence of
a patient’s immune system (i.e. increase baseline effector
supply rate or decrease effector death rate), such as adop-
tive cell therapy or vaccination, could drive tumours from
tumour escape to elimination or control at a small-tumour
steady state. Other immunotherapies may directly target
and manipulate the immune response to the tumour, such
as immune checkpoint therapies. Treatments that target
ρ, the maximum rate of tumour-stimulated supply of effec-
tor cells, and µ, the rate of tumour-induced effector cell
inactivation, are mainly beneficial to immunocompetent
patients that lie in a bistable region of tumour escape and
elimination. For immunocompromised patients, the most
promising therapy was found to be one that impacts η,
the tumour cell density at which increased effector cell
proliferation and infiltration due to the tumour become
limited. Reducing this parameter may drive the system to
a monostable parameter region exhibiting tumour equilib-
rium, or to a bistable region with only a subset of smaller
tumours under immune control. We note, however, that
tumour control in the latter region would likely be difficult
to achieve in practice (e.g. via surgery, in which the effec-
tor and tumour cell numbers are manipulated) due to the
small size of the basin of attraction of the dormant steady
state. For these patients, the system may be moved to a
monostable tumour equilibrium regime via a therapy that
perturbs µ or ρ in addition to η. The model also suggests
it may be more effective to give the majority of immuno-
compromised patients a combination therapy that initially
increases the patient’s immunocompetence; this way tu-
mour elimination/control may be achieved or become more
easily attainable with subsequent immunotherapies that
directly modulate the immune response to the tumour.
In practice, immunotherapy will likely impact multiple
parameters, as a result of interconnectedness of pathways
in the tumour microenvironment. Also, combination (im-
muno)therapies may be synergistic or antagonistic (Melero
et al., 2015; Rojas et al., 2015; Lai et al., 2017). These
observations nonetheless do not diminish the insight our
results provide. However, they raise questions about the
practical feasibility and complexity management of tuning
model parameters and (combination) therapies with high
enough accuracy to drive the patient and their tumour
into a desired parameter region. In our study we used
parameter values estimated in Kuznetsov et al. (1994) by
fitting their QSSA model to murine data (Siu et al., 1986).
The full model would in future have to be sufficiently tuned
against patient tumour volume data, in order to identify
realistic parameter regimes and increase the model’s pre-
dictive power. We therefore aim to fit our reduced model
to human data as well as to murine data from Siu et al.
(1986).
There are several ways in which the original model could
be modified to better describe tumour-immune interactions.
We could generalise the logistic tumour growth term to in-
clude competition between all cells in the tumour region for
resources, growth factors and space. The model assumption
of a constant supply of activated cytotoxic T cells (CTLs),
s > 0, is only valid when the region has been previously
exposed to tumour antigens, or if the organism has been
treated with a cancer vaccine or adoptive cell therapy as in
Kirschner and Panetta (1998). In a model without treat-
ment effects, we could omit the baseline effector influx term
(Kirschner and Panetta, 1998; Kronik et al., 2008; Itik and
Banks, 2010; Letellier et al., 2013) to take into account that
activation of CTLs is predominantly tumour-dependent,
and not instantenous. The current model also does not
capture immunosuppression as dominant at large tumour
sizes, since the number of effector cells does not decrease
with a growing tumour population in model simulations;
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this could also be an aspect for further exploration.
The simplifying assumptions in the original model by
Kuznetsov et al. (1994) allowed us to asymptotically reduce
it to a two-dimensional tumour-effector model, and to gain
a thorough understanding of its behaviour through a sys-
tematic dynamical systems analysis. Despite its limitations,
the model captures a variety of clinically observed phenom-
ena through dynamics that are subject to excitability and
a rich bifurcation structure. The model has thus demon-
strated the complexity of tumour-immune interactions, and
the heterogeneity in their final outcomes. Preferred strate-
gies for controlling tumour size may differ between patients
depending on the strength of their immune systems, which
is a result that supports personalised approaches to cancer
therapy. While the model, and the hypotheses generated
from it, must be validated with experimental/clinical data,
we emphasise that understanding the intricate behaviours
of such models is one of the pivotal steps towards overcom-
ing difficulties associated with their validation, and, in the
longer term, using validated and evidence-based models to
generate patient-specific predictions.
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Appendix A. Nullclines
Here we present equations for nullclines of the reduced,
long-timescale system (17). On the w1- and w2-nullclines
we have that w˙1 = 0 and w˙2 = 0 respectively. We find that
w1-nullclines are a subset of solutions to the quadratic in
w2 given by
a¯(w1)w22 + b¯(w1)w2 + c¯(w1) = 0, (A.1a)
where a¯, b¯ and c¯ are polynomials in w1 given by
a¯(w1) := a¯1w1 + a¯0,
b¯(w1) := b¯2w21 + b¯1w1 + b¯0,
c¯(w1) := c¯3w31 + c¯2w21 + c¯1w1 + c¯0,
(A.1b)
with coefficients dependent on model parameters as follows
a¯0 = σκ1 ((ηκ1 − 1) (δκ1 − µ) + ρκ1) ,
a¯1 = −µ ((ηκ1 − 1) (δκ1 − µ) + ρκ1) ,
b¯0 = σ ((ηκ1 + 1) ((ηκ1 − 1) (δκ1 − µ) + ρκ1)
+σκ1κ2 (ηκ1 − 1)) ,
b¯1 = (ρ− ηµ− δ)((ηκ1 − 1)(δκ1 − µ) + ρκ1)
+ σκ2(µ− ρκ1 + δκ1(1− 2ηκ1)),
b¯2 = µκ21κ22 (ρ− ηµ+ δ (2ηκ1 − 1)) ,
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c¯0 = ησ((ηκ1 − 1)(δκ1 − µ+ σκ1κ2) + ρκ1),
c¯1 = −η (δ ((ηκ1 − 1) (δκ1 − µ) + ρκ1)
+σκ2 (ηκ1(δκ1 + µ)− 2µ− ρκ1 + σκ1κ2)) ,
c¯2 = ηκ2 (δκ1(δ + ηµ− ρ) + σκ2 (δκ1 + µ)− 2δµ) ,
c¯3 = −δηµκ22.
(A.1c)
Analogous conditions hold for the w2-nullclines, which
satisfy
w2 = 0, and a˜w22 + b˜(w1)w2 + c˜(w1) = 0, (A.2a)
where a˜, b˜ and c˜ are given by
a˜ = a˜0,
b˜(w1) = b˜1w1 + b˜0,
c˜(w1) = c˜2w21 + c˜1w1 + c˜0,
(A.2b)
and
a˜0 = αβκ21,
b˜0 = α (κ1 (κ1 − β)− αβ (κ1 + β)) ,
b˜1 = 2αβκ1κ2,
c˜0 = α (κ1 + α (β + κ1)) ,
c˜1 = κ2 (αβ(α− 1)− κ1(α+ 1)) ,
c˜2 = −αβκ22.
(A.2c)
Appendix B. Asymptotic approximation of the non-
zero-tumour steady states and con-
ditions for their physicality
Here we detail the derivation of asymptotic approxi-
mations of the nonzero-tumour steady states presented in
Section 5.1.1, and discuss where they are physically realistic
(real and nonnegative).
The nonzero-tumour steady states are defined as (e∗,m∗) =
( ακ2 (1− βm),m), where m is a root of the cubic (25a). We
assume 0 < ξ  1, µ = ξµˆ and β = ξβˆ. Under this
rescaling, (25a) becomes
p(m) = ξ2aˆ3m3 + ξaˆ2m2 + aˆ1m+ a0
+ ξ2aˆ21m2 + ξaˆ11m = 0,
(B.1a)
where
a0 = η(σκ2α − δ),
aˆ1 = σκ2α + ρ− δ,
aˆ11 = η(βˆδ − µˆ),
aˆ2 = −µˆ+ βˆ(δ − ρ),
aˆ21 = ηµˆβˆ,
aˆ3 = µˆβˆ.
(B.1b)
We seek approximate solutions to (B.1a) of the form m =
ξ−γmˆ with γ a constant and mˆ = O(1), giving
p(ξγmˆ) = ξ2−3γ aˆ3mˆ3 + ξ1−2γ aˆ2mˆ2 + ξ−γ aˆ1mˆ
+ aˆ0 + ξ2−2γ aˆ21mˆ2 + ξ1−γ aˆ11mˆ = 0.
(B.2)
aˆ2
aˆ1 aˆ1 < 0 0 < aˆ1 < aˆ#1 aˆ
#
1 < aˆ1
aˆ2 < 0 mˆ4 < 0 < mˆ3 mˆ3,4 > 0 mˆ3,4 complex
aˆ2 > 0 mˆ4 < 0 < mˆ3 mˆ3,4 < 0 mˆ3,4 complex
Table B.1: Table showing where in (aˆ1, aˆ2) coefficient space asymp-
totic approximations (B.4) of the large roots m∗3,4 of the cubic (25a)
are real and nonnegative. Note that aˆ#1 := aˆ22/4aˆ3.
We find pairwise dominant balances among terms in the
cubic to simplify it.
First, balancing the third and fourth terms gives γ = 0.
With γ = 0, we obtain a leading-order solution mˆ2 = O(1)
to (B.2) of the form
mˆ2 := −a0
aˆ1
= η(αδ − σκ2)
σκ2 − αδ + αρ, (B.3a)
which gives
m∗2 ∼ m2 ∼ mˆ2 and e∗2 ∼
α
κ2
(1− ξβˆmˆ2) ∼ α
κ2
=: eˆ2.
(B.3b)
These approximate solutions correspond to an intermediate-
sized-tumour steady state given by (e∗2,m∗2) ∼ (eˆ2, mˆ2).
Noting ρ > 0, it is straightforward to show that this steady
state is physically realistic if and only if σκ2α ≤ δ < ρ+ σκ2α
(or equivalently a0η ≤ 0 < aˆ1).
We recover the other roots of the cubic by balancing
the first, second and third terms of (B.2), by setting γ = 1.
This gives leading-order solutions mˆ3,4 = O(1) to (B.2) of
the form
mˆ3,4 :=
−aˆ2 ±
√
aˆ22 − 4aˆ3aˆ1
2aˆ3
, (B.4a)
so that
m∗3,4 ∼ m3,4 ∼
1
ξ
mˆ3,4 and e∗3,4 ∼
α
κ2
(1− βˆmˆ3,4) =: eˆ3,4.
(B.4b)
These approximate solutions define two large-tumour steady
states given by (e∗3,4,m∗3,4) ∼ (eˆ3,4, mˆ3,4/ξ). We note that
eˆ3,4 and mˆ3,4 are both nonnegative if 0 ≤ mˆ3,4 ≤ 1βˆ . Given
aˆ3 > 0, we identify regions of (aˆ1, aˆ2) coefficient space with
different numbers of real and nonnegative roots mˆ3,4 (see
Table B.1). This allows us to identify regions in which there
are zero, one or two physically realistic steady states with
large tumours. In summary, provided mˆ3,4 ≤ 1βˆ , there is a
single large-tumour steady state solution when aˆ1 < 0, two
such solutions when 0 < aˆ1 < aˆ22/4aˆ3 =: aˆ# and aˆ2 < 0,
and none otherwise.
Appendix C. Comparison with the QSSA model
by Kuznetsov et al. (1994)
Here we discuss how the behaviour of our asymptotic
long-timescale approximation (17) (or equivalently (18)) of
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the original model (1) by Kuznetsov et al. (1994) differs
from the QSSA model that was proposed by Kuznetsov
et al. (1994), and is given in its dimensionless form as
de
dτ = σ +
ρem
η +m − δe− µem, (C.1a)
dm
dτ = αm(1− βm)− κ2em, (C.1b)
with c = em, initial conditions e(0) = e0 and m(0) = m0,
and dimensionless parameter groupings defined in (2).
Steady states (25b), their asymptotic approximations
(26) and (27), and the condition for local stability of the
tumour-free steady state (35) are equivalent in model
(18) and the QSSA model (C.1). We derive a condi-
tion, analogous to (39), for stability of the intermediate-
sized-tumour steady state in the QSSA model. The Jaco-
bian of the QSSA model, at leading order in ξ, is given
by J (e∗,m∗) = A(e∗,m∗), with A defined in (33). For
(e∗,m∗) = (e∗2,m∗2) as in (26), we obtain that
det(A(e∗2,m∗2)) > 0 as in (38), (C.2)
and
tr(A(e∗2,m∗2)) = −
σκ2
α
< 0, (C.3)
for physically realistic values of (e∗2,m∗2) (see Section 5.1.3).
If the intermediate-sized-tumour steady state is physically
realistic, then it is stable (see Figure C.1). This is different
from model (18) where the trace condition (39) is not
trivially satisfied.
In Figures C.1 and 9 we observe that regions where
tumour elimination may occur (yellow and blue, both with
diagonal lines) correspond in both models. Due to differ-
ences in local stability of the intermediate-sized-tumour
steady state mono- and bistable regions with dormancy
(yellow and blue, both with cross-hatching) are larger in
the QSSA model than in the long-timescale model (18);
tumour equilibrium is therefore more plausible in the QSSA
model. Simulations of the QSSA model also show simpler
behaviour that is not excitable, and larger basins of attrac-
tion of the dormant steady state, than in model (18) (see
Figure C.2). The homoclinic orbit that arises in model
(18) (see Figures 8B and 8C) does not exist in the QSSA
model as it was shown in Kuznetsov et al. (1994), using the
Dulac-Bendixson criterion, that there are no closed orbit
solutions in the positive quadrant of (e,m) phase plane.
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Figure C.1: Bifurcation structure of the QSSA model (C.1) differs from that of the long-timescale model (18) as σ and δ are varied in the
vicinity of the default parameter regime (see Table 2); the key difference is that the intermediate-sized-tumour steady state is stable when
physically realistic. Plot (a) illustrates this by showing how (σ, δ) parameter space is split into distinct regions depending on existence and
stability of steady states in the QSSA model. Plot (b) is a bifurcation diagram of steady state tumour cell numbers in the QSSA model as σ is
varied, and δ is fixed at its default value, δ0 = 0.374. Plots for the long-timescale model (17) that are comparable to (a) and (b) are Figures 6
and 9 respectively; see these figures for details on how (a) and (b) are generated and legend.
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Figure C.2: Series of plots (a) show phase portraits of (i) the QSSA model (C.1) in (e,m) phase space, (ii) the same model in (w1, w2) phase
space, and (iii) the asymptotic long-timescale model (17) in (w1, w2) phase space. The QSSA model (see (i) and (ii)) does not exhibit excitable
dynamics that are observed in model (17) (see (iii) and also Figures 3 and 8); trajectories do not follow nullclines, and no limit cycles are
observed. See Figure 8 for phase portrait legend. In all three plots, equivalent initial conditions, appropriately transformed, are used for
computing solution trajectories via methods described in Section 3.3. Trajectories in plot (a)(ii) are generated by numerically solving equations
(C.1) first; the obtained solutions for e and m are then transformed via w1 = e+ κ1em and w2 = m+ κ2em to compute numerical solutions
for total effector and tumour cell numbers, w1 and w2. Series of plots (b) show different solutions for model variables (i) w1(τ), (ii) w2(τ) and
(iii) v(τ) over time (0 ≤ τ ≤ 60) for the one set of initial conditions from (a), given as w1(0) = w2(0) = 100, v = v†(w(0)) = 90.48. Solid black,
dashed light grey and dotted dark grey curves respectively correspond to solutions of the full model (3), the long-timescale model (17) and
the QSSA model (C.1). The QSSA solution does not agree with the matching full and long-timescale solutions. For all plots in (a) and (b),
parameter σ is fixed at σ = 0.1, and other parameters at their default values (see Table 2).
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Appendix D. Schematics of phase portraits in Figure 3
(A) 0 < σ < σSH (B) σSH < σ < σHopf (C) σHopf < σ < σSO
(D) σSO < σ < σT (E) σ > σT
Figure D.1: Schematic diagrams (not to scale) of phase portraits in Figure 8 as σ varies. The vertical direction represents tumour cells, while
the horizontal direction represents effector cells. Solid grey curves denote stable and unstable manifolds, solid black curves show example
trajectories, and dashed grey circles represent unstable orbits. As in Figure 8, stable, unstable and saddle nodes are respectively marked with
red discs, blue squares and light blue discs with an outline of a darker shade of blue.
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Appendix E. Bifurcation structure as parameter µ varies
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(a) µ = µ0/1.8 = 0.0017
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(b) µ = 2µ0 = 0.006
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(c) µ = 32.2µ0 = 0.1
Figure E.1: Series of plots (a)–(c) showing how the bifurcation structure of the long-timescale system (17) changes as µ is varied from its
default value µ0 = 0.003. Effects of increasing µ on the system’s bifurcation structure are similar to effects of decreasing ρ (see Figure 10).
For each value of µ, we present three bifurcation diagrams: plots of (σ, δ) parameter space showing (i) regions with different numbers of
physically realistic steady states (see Figure 5 for legend and details), and (ii) regions with different numbers of stable steady states (see
Figure 9 for legend and details); (iii) bifurcation diagrams of tumour steady state numbers, m∗, as σ is varied and δ is fixed at its default value
(see Figure 6 for legend and details).
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